Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line

Sulaiman S. Alhudaithi; Mohd Abul Kalam; Lama Binobaid; Raisuddin Ali; Mohammed M. Almutairi; Wajhul Qamar; Hessa Bin Hithlayn; Atheer Almutairi; Abdullah K. Alshememry

doi:10.1016/j.jsps.2024.102064

Q1 2024

Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line

Sulaiman S. Alhudaithi · Mohd Abul Kalam · Lama Binobaid · Raisuddin Ali · Mohammed M. Almutairi · Wajhul Qamar · Hessa Bin Hithlayn · Atheer Almutairi · Abdullah K. Alshememry

10.1016/j.jsps.2024.102064 388 Views 27 Citations

Citations

388

Views

Abstract not available for this publication.

Cite this Article (APA)

Sulaiman, S. A., Mohd, A. K., Lama, B., Raisuddin, A., Mohammed, M. A., Wajhul, Q., Hessa, B. H., Atheer, A., Abdullah, K. A. (2024). Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line. Saudi Pharmaceutical Journal. https://doi.org/10.1016/j.jsps.2024.102064